Dr. Reisner began his career in the pharmaceutical industry at Boehringer Ingelheim where he focused on drug development in the Respimat(R) device, as well as the development of reformulated products using alternative propellants. Additionally, he assisted in securing approval of Combivent(R) Inhalation Aerosol in several European countries and Australia, and led the clinical components of a large COPD disease management program in collaboration with Penn-State Geisinger Health System.
Dr. Reisner graduated from the University of Witwatersrand Medical School in South Africa and completed his residency in Internal Medicine at Danbury Hospital, Danbury, Connecticut, a Yale-affiliated training program. He completed his fellowship training in Allergy and Immunology at National Jewish, Denver, Colorado, and he is a Diplomat of the American Board of Internal Medicine and the American Board of Allergy and Immunology.
Michael Golden joins Pearl from GlaxoSmithKline where for 20 years, he
played significant roles in the development, regulatory submission and
approval of 8 marketed inhalation and nasally delivered drugs including
Flovent(R), Serevent(R), Advair(R), Ventolin(R), and Veramyst(R) Nasal
Spray. Most recently he was the Director, External Advocacy, Global CMC
Submissions, Regulatory Affairs at GSK. In this position, he was the
principal advocate and liaison between GSK and the FDA in support of
Quality by Design for all products. Additionally, Mr. Golden was a board
member of the International Pharmaceutical Aerosol Consortium on Regulation
and Science (IPAC-RS), where he led the consortium to find common ground
between the Industry and the FDA for many regulatory, quality, and
scientific topics. Mr. Golden's
|SOURCE Pearl Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved